Week 42, New INDs in CHN & New mood

So I am guessing Week 42 is a slow & tough week for lots of people.

It’s the second week back from the national holiday and the first one with a full weekend. With the date moving to Q4, there’s a lot of pressure on us all. In the CRO/CDMO world, we’re racing to close 2024. And on the sponsor side, I’m hearing that budgets are running out. With the pharma industry still not in a strong position overall. it’s going to take a long time to get back to where we were.

Right, now let’s take a look at the CDE reviewing bulletin board. On the biologics side, 23 new INDs are being filed with CDE, and most of them are familiar names. And it’s great to see a new IND from an old face.

From chemical side, the two biggest 2s are from Lilly and Novo Nordisk. And while on the topic of GLP-1, when will the shortage in China finally be over? It’s not just the patients who are affected; local biosimilar companies are being asked to use the brand drug (must be locally marketed, so I heard) as the positive control drug. Without a control drug, the trial can’t start.

This is for now, see you next week.